REDONDO BEACH, CA--(Marketwired - Mar 2, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing AXIM® Biotechnologies Inc.'s (
Cannabis may be a Schedule I Controlled Substance with 'no medical benefit' in the eyes of the Drug Enforcement Administration (DEA), but a growing number of clinical trials have proven that very real benefits exist. Cannabinoids may have anecdotal benefits when it comes to treating a variety of medical conditions, but effective treatments will require non-invasive delivery systems that provide a high level of bioavailability for CBD and other cannabinoids. These delivery systems have increasingly become an area of focus within the therapeutic side of the cannabis industry as the benefits of CBD and tetrahydrocannabinol (THC) become more apparent.
AXIM Biotech recently announced significant improvements to the bioavailability of its CanChew+ thanks to microencapsulation. According to its press release, the new technology has increased bioavailability from less than 50% after two hours of chewing to more than 80% in 30 minutes of chewing. The company also made improvements to the gum's size and flavor, which makes it a more viable option for patients seeking treatment.
A 2005 study published in the Pain Research & Management Journal found that THC bioavailability varied between 4% and 30% depending on the delivery method. Smoked cannabis had the highest THC bioavailability with an average of 30%, whereas cannabis edibles had lower THC bioavailability of between 4% and 12%. Unfortunately, smoke from marijuana combustion has been shown to contain many of the same harmful toxins as cigarette smoke.
AXIM Biotech has spent the last 14 years developing its oral, trans-mucosal, controlled-release delivery system that exhibits similar or improved bioavailability relative to smoked cannabis. The chewing gum delivery mechanism avoids the first pass metabolism that's responsible for reducing the bioavailability of cannabinoids and for the hepatic metabolism of THC to 8-, 9- and 11-OH-THC, which are all toxic metabolites responsible for the side effects of cannabis consumption. These are nausea, paranoia, etc.
The company announced last month that it would begin clinical trials at Wageningen University in the Netherlands for its CanChew+ CBD gum for the treatment of irritable bowel syndrome (IBS) -- the most common disorder diagnosed by gastroenterologists that accounts for up to 12% of total visits to primary care providers. The trial will include a group of at least 40 patients diagnosed with severe IBS by ROME III criteria to assess the effectiveness of CanChew+ in alleviating symptoms. This particular CanChew+ gum contains 50mg of CBD.
Please follow the link to read the full article: http://analysis.secfilings.com/articles/152-n...ailability
About SECFilings.com
Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx .
SECFilings.com Paul Archie 406-862-2242 parchie@secfilings.com
